- Home
- HBB vs RVPHW Comparison
HBB vs RVPHW Comparison
Compare HBB & RVPHW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBB
- RVPHW
- Stock Information
- Founded
- HBB 1904
- RVPHW N/A
- Country
- HBB United States
- RVPHW United States
- Employees
- HBB N/A
- RVPHW 15
- Industry
- HBB Home Furnishings
- RVPHW Biotechnology: Pharmaceutical Preparations
- Sector
- HBB Consumer Discretionary
- RVPHW Health Care
- Exchange
- HBB Nasdaq
- RVPHW Nasdaq
- Market Cap
- HBB 292.6M
- RVPHW N/A
- IPO Year
- HBB 2017
- RVPHW 2018
- Fundamental
- Price
- HBB $16.48
- RVPHW $0.14
- Analyst Decision
- HBB
- RVPHW
- Analyst Count
- HBB 0
- RVPHW 0
- Target Price
- HBB N/A
- RVPHW N/A
- AVG Volume (30 Days)
- HBB 54.1K
- RVPHW N/A
- Earning Date
- HBB 10-30-2024
- RVPHW N/A
- Dividend Yield
- HBB 2.75%
- RVPHW N/A
- EPS Growth
- HBB 107.04
- RVPHW N/A
- EPS
- HBB 1.88
- RVPHW N/A
- Revenue
- HBB $647,834,000.00
- RVPHW N/A
- Revenue This Year
- HBB $4.60
- RVPHW N/A
- Revenue Next Year
- HBB N/A
- RVPHW N/A
- P/E Ratio
- HBB $8.82
- RVPHW N/A
- Revenue Growth
- HBB 5.30
- RVPHW N/A
- 52 Week Low
- HBB $14.34
- RVPHW N/A
- 52 Week High
- HBB $31.78
- RVPHW N/A
- Technical
- Relative Strength Index (RSI)
- HBB 22.07
- RVPHW N/A
- Support Level
- HBB $16.12
- RVPHW N/A
- Resistance Level
- HBB $18.39
- RVPHW N/A
- Average True Range (ATR)
- HBB 0.89
- RVPHW 0.00
- MACD
- HBB 0.01
- RVPHW 0.00
- Stochastic Oscillator
- HBB 0.02
- RVPHW 0.00
About HBB Hamilton Beach Brands Holding Company
Hamilton Beach Brands Holding Co, through its subsidiaries, is engaged in consumer, commercial, and specialty small appliances and specialty retail. It designs, markets, and distributes small branded electric household and specialty housewares small appliances, as well as commercial products for restaurants, bars, and hotels.
About RVPHW Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.